US Liquid Biopsy Market

US Liquid Biopsy Market Size, Share, Growth Analysis, By Biomarker Types(Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA)), By Application(Cancer Therapeutic Application, Reproductive Health), By Sample(Blood Sample, Urine Sample), By End User(Hospitals and Laboratories, Academic and Research Centers) - Industry Forecast 2023-2030


Report ID: UCMIR35J2123 | Region: Regional | Published Date: Upcoming | Pages: 165 | Tables: 55 | Figures: 60

US Liquid Biopsy Market Insights

Market Overview:

The US liquid biopsy market has demonstrated substantial growth, commencing with a market size of USD 362.82 million in 2022 and poised for remarkable expansion, with projections to reach approximately USD 1,816.95 million by 2032. This growth trajectory is underpinned by a compelling compound annual growth rate (CAGR) of 17.48% during the forecast period spanning from 2023 to 2032. The escalating demand for non-invasive diagnostic solutions, advancements in genomics and molecular diagnostics, and the potential to detect various cancers and diseases at an early stage are driving the adoption of liquid biopsy technologies. The benefits of reduced patient discomfort, quicker results, and real-time monitoring are augmenting market growth. Moreover, ongoing research and development efforts, collaborations between industry players and research institutions, and favorable regulatory environments are contributing to the market's expansion. As precision medicine gains prominence and the importance of personalized treatment strategies becomes increasingly evident, the US liquid biopsy market is anticipated to witness sustained investments in technology refinement and clinical applications, further propelling its substantial growth in the coming years.

US Liquid Biopsy Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
Get Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Life Sciences Tools & Services by segment aggregation, the contribution of the Life Sciences Tools & Services in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The US Liquid Biopsy Market is segmented by Biomarker Types, Application, Sample, End User. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

US Liquid Biopsy Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Biomarker Types the market is segmented as, Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular vesicles (EVS), Other Biomarkers
  • Based on Application the market is segmented as, Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application
  • Based on Sample the market is segmented as, Blood Sample, Urine Sample, Other
  • Based on End User the market is segmented as, Hospitals and Laboratories, Academic and Research Centers, Other End Users, KEY MARKET PLAYERS, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V.

Regional Analysis:

US Liquid Biopsy Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

US Liquid Biopsy Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
SPEAK TO AN ANALYST

US Liquid Biopsy Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on US Liquid Biopsy Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect US Liquid Biopsy Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key US Liquid Biopsy Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the US Liquid Biopsy Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • sights
  • The US liquid biopsy market size was exhibited at USD 362.82 million in 2022 and is projected to hit around USD 1,816.95 million by 2032, growing at a CAGR of 17.48% during the forecast period from 2023 to 2032.
  • Key Points:
  • On the basis of biomarker types, the circulating tumor cells (CTC) segment is anticipated to dominate the market from 2023 to 2032.
  • On the basis of application, the cancer therapeutic application segment had the major market share in 2021.
  • On the basis of the sample, the blood sample segment is predicted to expand at the biggest rate from 2023 to 2032.
  • On the basis of end-user, the hospitals and laboratories segment had the major market share in 2021.
  • Market Overview
  • A technique that involves diagnosing and tracking diseases like cancer is known as liquid biopsy. This technique involves sampling and analyzing biological tissues in a liquid condition. Liquid biopsies are mainly preferred to eliminate the discomfort associated with operations. For instance, blood and urine are the liquid samples utilized in the method. Both of these samples are obtained painlessly and readily. It is mainly a practical application of two developments in medical science, human genome sequencing and the growing sensitivity of detection measures and assays. Additionally, it provides a risk-free and efficient option for patients who are unable to have a tissue biopsy due to the risks associated, such as those with lung cancer who have tumors that are too close to the heart. Clinical utility challenges, lack of sensitivity, and specificity of liquid biopsy tests are some of the key factors hindering the growth of liquid biopsy.
  • COVID-19 Impact:
  • COVID-19 had a major influence on the number of patients receiving cancer screening, diagnosis, and treatment. Oncology clinics were re-profiled to treat COVID-19 patients due to increased demand caused by the rising number of COVID-19 patients being hospitalized. However, as governments gradually reduce travel restrictions, testing numbers are projected to rise once more. Since the COVID-19 pandemic, responding to increased cancer incidence has become a critical medical challenge on a worldwide scale. Because numerous COVID-19 patients had cancer, cancer has been recognized as a risk factor for COVID-19. More study in this area is expected to benefit cancer research by assisting in better understanding the dynamics of infection. This is also expected to raise demand for liquid biopsy products.
  • Market Dynamics:
  • Drivers: Rise in the prevalence of cancer
  • On a worldwide basis, the number of cancer patients has grown dramatically. For instance, according to World Health Organization, the leading cause of death is cancer, accounting for nearly 10 million deaths in 2020. Some of the causes of the increased incidence of cancer include environmental factors, cigarette smoking, viral disorders such as Hepatitis B and C, and lifestyle changes. Liquid biopsy provides several advantages over traditional cancer diagnostic procedures, including reduced cost, earlier prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). The liquid biopsy is expected to become the first choice for diagnosis of a wide variety of cancers, such as Central Nervous System (CNS) and pancreatic cancer.
  • Restraints: Certain liquid biopsies have reduced sensitivity
  • Detecting ctDNA in liquid biopsies is technically difficult since the quantities of DNA of any particular cancer mutation in a cancer patient's plasma might be very low, especially after therapy or surgery. According to the sampling statistics, there may be less than one detectable copy of the ctDNA with the cancer mutation in each sample of plasma from a patient. As a result, even if ctDNA is present in the plasma at a low level, it may not be found in the patient sample. This results in false-negative results in which ctDNA is not discovered despite its presence, decreasing the predictive value of liquid biopsy testing for cancer.
  • Opportunities: The increasing influence of companion diagnostics
  • Companion diagnostics are tests or assays that assist healthcare practitioners to make treatment decisions for patients based on the optimal response to therapy. Co-development of companion diagnostics with therapeutic goods has the potential to significantly transform the drug development process and accelerate the commercialization of drug candidates. This is done by producing safer medications with improved therapeutic efficacy rapidly and cost-effectively. The market for companion diagnostics has considerable growth potential due to the rising need for high-priced specialized therapies and safer medications. The increasing relevance of companion diagnostics is also propelling the liquid biopsy market growth.
  • Segments Insight
  • Biomarker Type Insights
  • Based on the biomarker type, the U.S. Liquid Biopsy Market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), extracellular vesicles (EVs), and other biomarkers. Due to the increased global cancer prevalence, the Circulating Tumor Cells(CTC) category is anticipated to dominate the liquid biopsy market over the forecast period. The cells that break out from primary or secondary cancers and enter the bloodstream are known as Circulating Tumor Cells. The predictive and prognostic biomarkers in various cancers, including lungs, breast, and prostate, are CTC. Additionally, the circulating tumor DNA segment is expected to grow significantly during the forecast period.
  • Sample Insights
  • Based on the sample, the U.S. Liquid Biopsy Market is segmented into blood samples, urine samples, and others. The Blood sample category is expected to expand at the fastest rate over the review period. A blood test is painless and has no risks, along with this, it cuts down cost and time to diagnose a problem. Blood-based liquid biopsy is popular as it can detect CTCs, cfDNAs, exosomes, and microvesicles. Additionally, the urine sample segment is expected to grow significantly over the forecast period. The urine-based sample collection has various advantages over blood sample collection including increased patient compliance for cancer screening and the ability to monitor patients more frequently.
  • Application Insights
  • Based on the application, the U.S. Liquid Biopsy Market is segmented into cancer therapeutic applications, reproductive health, and other therapeutic application. The cancer application category had the most market share in 2020. The growing prevalence of cancer and the increase in research studies on liquid biopsy for cancer applications are driving the growth of this market. A type of test that can be used for cancer screening at an early stage is a liquid biopsy. It can be used to determine how well the treatment is working and whether the cancer has returned. The ctDNA tests may be able to detect more cancers at an early stage, which reduces the risk of death from that cancer.
  • End-User Insights
  • Based on the end-user, the U.S. Liquid Biopsy Market is segmented into hospitals and laboratories, academic and research centers, and other end users. The laboratories market category had the most market share in 2021. The increased outsourcing of liquid biopsy testing to reference labs is driving the growth of this industry. The revenue growth of hospitals is mainly driven by the emergence of cancer specialty hospitals in developing countries with the availability of advanced procedures, such as liquid biopsy.
  • Recent Developments
  • In July 2021, Biocept, Inc. has received a South Korean Patent for the Primer-Switch technology, which uses real-time PCR and related analytical methods to discover rare mutations in circulating tumor DNA (ctDNA). In February 2021, Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurring illness from a single blood draw, has been made available by Guardant Health, Inc.
  • KEY MARKET SEGMENTS
  • By Biomarker Types
  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (CTDNA)
  • Extracellular vesicles (EVS)
  • Other Biomarkers
  • By Application
  • Cancer Therapeutic Application
  • Reproductive Health
  • Other Therapeutic Application
  • By Sample
  • Blood Sample
  • Urine Sample
  • Other
  • By End User
  • Hospitals and Laboratories
  • Academic and Research Centers
  • Other End Users
  • KEY MARKET PLAYERS
  • ANGLE plc, Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc.
  • Illumina Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.

SkyQuest's Expertise:

The US Liquid Biopsy Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Biomarker Types - Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular vesicles (EVS), Other Biomarkers
  • By Application - Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application
  • By Sample - Blood Sample, Urine Sample, Other
  • By End User - Hospitals and Laboratories, Academic and Research Centers, Other End Users, KEY MARKET PLAYERS, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V.
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • sights
  • The US liquid biopsy market size was exhibited at USD 362.82 million in 2022 and is projected to hit around USD 1,816.95 million by 2032, growing at a CAGR of 17.48% during the forecast period from 2023 to 2032.
  • Key Points:
  • On the basis of biomarker types, the circulating tumor cells (CTC) segment is anticipated to dominate the market from 2023 to 2032.
  • On the basis of application, the cancer therapeutic application segment had the major market share in 2021.
  • On the basis of the sample, the blood sample segment is predicted to expand at the biggest rate from 2023 to 2032.
  • On the basis of end-user, the hospitals and laboratories segment had the major market share in 2021.
  • Market Overview
  • A technique that involves diagnosing and tracking diseases like cancer is known as liquid biopsy. This technique involves sampling and analyzing biological tissues in a liquid condition. Liquid biopsies are mainly preferred to eliminate the discomfort associated with operations. For instance, blood and urine are the liquid samples utilized in the method. Both of these samples are obtained painlessly and readily. It is mainly a practical application of two developments in medical science, human genome sequencing and the growing sensitivity of detection measures and assays. Additionally, it provides a risk-free and efficient option for patients who are unable to have a tissue biopsy due to the risks associated, such as those with lung cancer who have tumors that are too close to the heart. Clinical utility challenges, lack of sensitivity, and specificity of liquid biopsy tests are some of the key factors hindering the growth of liquid biopsy.
  • COVID-19 Impact:
  • COVID-19 had a major influence on the number of patients receiving cancer screening, diagnosis, and treatment. Oncology clinics were re-profiled to treat COVID-19 patients due to increased demand caused by the rising number of COVID-19 patients being hospitalized. However, as governments gradually reduce travel restrictions, testing numbers are projected to rise once more. Since the COVID-19 pandemic, responding to increased cancer incidence has become a critical medical challenge on a worldwide scale. Because numerous COVID-19 patients had cancer, cancer has been recognized as a risk factor for COVID-19. More study in this area is expected to benefit cancer research by assisting in better understanding the dynamics of infection. This is also expected to raise demand for liquid biopsy products.
  • Market Dynamics:
  • Drivers: Rise in the prevalence of cancer
  • On a worldwide basis, the number of cancer patients has grown dramatically. For instance, according to World Health Organization, the leading cause of death is cancer, accounting for nearly 10 million deaths in 2020. Some of the causes of the increased incidence of cancer include environmental factors, cigarette smoking, viral disorders such as Hepatitis B and C, and lifestyle changes. Liquid biopsy provides several advantages over traditional cancer diagnostic procedures, including reduced cost, earlier prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). The liquid biopsy is expected to become the first choice for diagnosis of a wide variety of cancers, such as Central Nervous System (CNS) and pancreatic cancer.
  • Restraints: Certain liquid biopsies have reduced sensitivity
  • Detecting ctDNA in liquid biopsies is technically difficult since the quantities of DNA of any particular cancer mutation in a cancer patient's plasma might be very low, especially after therapy or surgery. According to the sampling statistics, there may be less than one detectable copy of the ctDNA with the cancer mutation in each sample of plasma from a patient. As a result, even if ctDNA is present in the plasma at a low level, it may not be found in the patient sample. This results in false-negative results in which ctDNA is not discovered despite its presence, decreasing the predictive value of liquid biopsy testing for cancer.
  • Opportunities: The increasing influence of companion diagnostics
  • Companion diagnostics are tests or assays that assist healthcare practitioners to make treatment decisions for patients based on the optimal response to therapy. Co-development of companion diagnostics with therapeutic goods has the potential to significantly transform the drug development process and accelerate the commercialization of drug candidates. This is done by producing safer medications with improved therapeutic efficacy rapidly and cost-effectively. The market for companion diagnostics has considerable growth potential due to the rising need for high-priced specialized therapies and safer medications. The increasing relevance of companion diagnostics is also propelling the liquid biopsy market growth.
  • Segments Insight
  • Biomarker Type Insights
  • Based on the biomarker type, the U.S. Liquid Biopsy Market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), extracellular vesicles (EVs), and other biomarkers. Due to the increased global cancer prevalence, the Circulating Tumor Cells(CTC) category is anticipated to dominate the liquid biopsy market over the forecast period. The cells that break out from primary or secondary cancers and enter the bloodstream are known as Circulating Tumor Cells. The predictive and prognostic biomarkers in various cancers, including lungs, breast, and prostate, are CTC. Additionally, the circulating tumor DNA segment is expected to grow significantly during the forecast period.
  • Sample Insights
  • Based on the sample, the U.S. Liquid Biopsy Market is segmented into blood samples, urine samples, and others. The Blood sample category is expected to expand at the fastest rate over the review period. A blood test is painless and has no risks, along with this, it cuts down cost and time to diagnose a problem. Blood-based liquid biopsy is popular as it can detect CTCs, cfDNAs, exosomes, and microvesicles. Additionally, the urine sample segment is expected to grow significantly over the forecast period. The urine-based sample collection has various advantages over blood sample collection including increased patient compliance for cancer screening and the ability to monitor patients more frequently.
  • Application Insights
  • Based on the application, the U.S. Liquid Biopsy Market is segmented into cancer therapeutic applications, reproductive health, and other therapeutic application. The cancer application category had the most market share in 2020. The growing prevalence of cancer and the increase in research studies on liquid biopsy for cancer applications are driving the growth of this market. A type of test that can be used for cancer screening at an early stage is a liquid biopsy. It can be used to determine how well the treatment is working and whether the cancer has returned. The ctDNA tests may be able to detect more cancers at an early stage, which reduces the risk of death from that cancer.
  • End-User Insights
  • Based on the end-user, the U.S. Liquid Biopsy Market is segmented into hospitals and laboratories, academic and research centers, and other end users. The laboratories market category had the most market share in 2021. The increased outsourcing of liquid biopsy testing to reference labs is driving the growth of this industry. The revenue growth of hospitals is mainly driven by the emergence of cancer specialty hospitals in developing countries with the availability of advanced procedures, such as liquid biopsy.
  • Recent Developments
  • In July 2021, Biocept, Inc. has received a South Korean Patent for the Primer-Switch technology, which uses real-time PCR and related analytical methods to discover rare mutations in circulating tumor DNA (ctDNA). In February 2021, Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurring illness from a single blood draw, has been made available by Guardant Health, Inc.
  • KEY MARKET SEGMENTS
  • By Biomarker Types
  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (CTDNA)
  • Extracellular vesicles (EVS)
  • Other Biomarkers
  • By Application
  • Cancer Therapeutic Application
  • Reproductive Health
  • Other Therapeutic Application
  • By Sample
  • Blood Sample
  • Urine Sample
  • Other
  • By End User
  • Hospitals and Laboratories
  • Academic and Research Centers
  • Other End Users
  • KEY MARKET PLAYERS
  • ANGLE plc, Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc.
  • Illumina Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on US Liquid Biopsy Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on US Liquid Biopsy Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • sights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The US liquid biopsy market size was exhibited at USD 362.82 million in 2022 and is projected to hit around USD 1,816.95 million by 2032, growing at a CAGR of 17.48% during the forecast period from 2023 to 2032.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Key Points:
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On the basis of biomarker types, the circulating tumor cells (CTC) segment is anticipated to dominate the market from 2023 to 2032.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On the basis of application, the cancer therapeutic application segment had the major market share in 2021.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On the basis of the sample, the blood sample segment is predicted to expand at the biggest rate from 2023 to 2032.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On the basis of end-user, the hospitals and laboratories segment had the major market share in 2021.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Market Overview
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • A technique that involves diagnosing and tracking diseases like cancer is known as liquid biopsy. This technique involves sampling and analyzing biological tissues in a liquid condition. Liquid biopsies are mainly preferred to eliminate the discomfort associated with operations. For instance, blood and urine are the liquid samples utilized in the method. Both of these samples are obtained painlessly and readily. It is mainly a practical application of two developments in medical science, human genome sequencing and the growing sensitivity of detection measures and assays. Additionally, it provides a risk-free and efficient option for patients who are unable to have a tissue biopsy due to the risks associated, such as those with lung cancer who have tumors that are too close to the heart. Clinical utility challenges, lack of sensitivity, and specificity of liquid biopsy tests are some of the key factors hindering the growth of liquid biopsy.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • COVID-19 Impact:
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • COVID-19 had a major influence on the number of patients receiving cancer screening, diagnosis, and treatment. Oncology clinics were re-profiled to treat COVID-19 patients due to increased demand caused by the rising number of COVID-19 patients being hospitalized. However, as governments gradually reduce travel restrictions, testing numbers are projected to rise once more. Since the COVID-19 pandemic, responding to increased cancer incidence has become a critical medical challenge on a worldwide scale. Because numerous COVID-19 patients had cancer, cancer has been recognized as a risk factor for COVID-19. More study in this area is expected to benefit cancer research by assisting in better understanding the dynamics of infection. This is also expected to raise demand for liquid biopsy products.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Market Dynamics:
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Drivers: Rise in the prevalence of cancer
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • On a worldwide basis, the number of cancer patients has grown dramatically. For instance, according to World Health Organization, the leading cause of death is cancer, accounting for nearly 10 million deaths in 2020. Some of the causes of the increased incidence of cancer include environmental factors, cigarette smoking, viral disorders such as Hepatitis B and C, and lifestyle changes. Liquid biopsy provides several advantages over traditional cancer diagnostic procedures, including reduced cost, earlier prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). The liquid biopsy is expected to become the first choice for diagnosis of a wide variety of cancers, such as Central Nervous System (CNS) and pancreatic cancer.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Restraints: Certain liquid biopsies have reduced sensitivity
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Detecting ctDNA in liquid biopsies is technically difficult since the quantities of DNA of any particular cancer mutation in a cancer patient's plasma might be very low, especially after therapy or surgery. According to the sampling statistics, there may be less than one detectable copy of the ctDNA with the cancer mutation in each sample of plasma from a patient. As a result, even if ctDNA is present in the plasma at a low level, it may not be found in the patient sample. This results in false-negative results in which ctDNA is not discovered despite its presence, decreasing the predictive value of liquid biopsy testing for cancer.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Opportunities: The increasing influence of companion diagnostics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Companion diagnostics are tests or assays that assist healthcare practitioners to make treatment decisions for patients based on the optimal response to therapy. Co-development of companion diagnostics with therapeutic goods has the potential to significantly transform the drug development process and accelerate the commercialization of drug candidates. This is done by producing safer medications with improved therapeutic efficacy rapidly and cost-effectively. The market for companion diagnostics has considerable growth potential due to the rising need for high-priced specialized therapies and safer medications. The increasing relevance of companion diagnostics is also propelling the liquid biopsy market growth.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Segments Insight
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Biomarker Type Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on the biomarker type, the U.S. Liquid Biopsy Market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), extracellular vesicles (EVs), and other biomarkers. Due to the increased global cancer prevalence, the Circulating Tumor Cells(CTC) category is anticipated to dominate the liquid biopsy market over the forecast period. The cells that break out from primary or secondary cancers and enter the bloodstream are known as Circulating Tumor Cells. The predictive and prognostic biomarkers in various cancers, including lungs, breast, and prostate, are CTC. Additionally, the circulating tumor DNA segment is expected to grow significantly during the forecast period.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Sample Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on the sample, the U.S. Liquid Biopsy Market is segmented into blood samples, urine samples, and others. The Blood sample category is expected to expand at the fastest rate over the review period. A blood test is painless and has no risks, along with this, it cuts down cost and time to diagnose a problem. Blood-based liquid biopsy is popular as it can detect CTCs, cfDNAs, exosomes, and microvesicles. Additionally, the urine sample segment is expected to grow significantly over the forecast period. The urine-based sample collection has various advantages over blood sample collection including increased patient compliance for cancer screening and the ability to monitor patients more frequently.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on the application, the U.S. Liquid Biopsy Market is segmented into cancer therapeutic applications, reproductive health, and other therapeutic application. The cancer application category had the most market share in 2020. The growing prevalence of cancer and the increase in research studies on liquid biopsy for cancer applications are driving the growth of this market. A type of test that can be used for cancer screening at an early stage is a liquid biopsy. It can be used to determine how well the treatment is working and whether the cancer has returned. The ctDNA tests may be able to detect more cancers at an early stage, which reduces the risk of death from that cancer.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • End-User Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Based on the end-user, the U.S. Liquid Biopsy Market is segmented into hospitals and laboratories, academic and research centers, and other end users. The laboratories market category had the most market share in 2021. The increased outsourcing of liquid biopsy testing to reference labs is driving the growth of this industry. The revenue growth of hospitals is mainly driven by the emergence of cancer specialty hospitals in developing countries with the availability of advanced procedures, such as liquid biopsy.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Recent Developments
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • In July 2021, Biocept, Inc. has received a South Korean Patent for the Primer-Switch technology, which uses real-time PCR and related analytical methods to discover rare mutations in circulating tumor DNA (ctDNA). In February 2021, Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurring illness from a single blood draw, has been made available by Guardant Health, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Biomarker Types
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Circulating Tumor Cells (CTCs)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Circulating Tumor DNA (CTDNA)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Extracellular vesicles (EVS)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other Biomarkers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cancer Therapeutic Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Reproductive Health
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other Therapeutic Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Sample
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Blood Sample
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Urine Sample
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By End User
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospitals and Laboratories
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Academic and Research Centers
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Other End Users
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • ANGLE plc, Biocept Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Bio-Rad Laboratories Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Epigenomics AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Exact Sciences Corporation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • F. Hoffmann-La Roche AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Guardant Health Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Illumina Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • MDxHealth SA
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Menarini Silicon Biosystems
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • QIAGEN N.V.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Thermo Fisher Scientific Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the US Liquid Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the US Liquid Biopsy Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the US Liquid Biopsy Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the US Liquid Biopsy Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

The global market for US Liquid Biopsy was estimated to be valued at US$ XX Mn in 2021.

The global US Liquid Biopsy Market is estimated to grow at a CAGR of XX% by 2028.

The global US Liquid Biopsy Market is segmented on the basis of Biomarker Types, Application, Sample, End User.

Based on region, the global US Liquid Biopsy Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global US Liquid Biopsy Market are sights, The US liquid biopsy market size was exhibited at USD 362.82 million in 2022 and is projected to hit around USD 1,816.95 million by 2032, growing at a CAGR of 17.48% during the forecast period from 2023 to 2032. , Key Points:, On the basis of biomarker types, the circulating tumor cells (CTC) segment is anticipated to dominate the market from 2023 to 2032., On the basis of application, the cancer therapeutic application segment had the major market share in 2021., On the basis of the sample, the blood sample segment is predicted to expand at the biggest rate from 2023 to 2032., On the basis of end-user, the hospitals and laboratories segment had the major market share in 2021., Market Overview, A technique that involves diagnosing and tracking diseases like cancer is known as liquid biopsy. This technique involves sampling and analyzing biological tissues in a liquid condition. Liquid biopsies are mainly preferred to eliminate the discomfort associated with operations. For instance, blood and urine are the liquid samples utilized in the method. Both of these samples are obtained painlessly and readily. It is mainly a practical application of two developments in medical science, human genome sequencing and the growing sensitivity of detection measures and assays. Additionally, it provides a risk-free and efficient option for patients who are unable to have a tissue biopsy due to the risks associated, such as those with lung cancer who have tumors that are too close to the heart. Clinical utility challenges, lack of sensitivity, and specificity of liquid biopsy tests are some of the key factors hindering the growth of liquid biopsy., COVID-19 Impact:, COVID-19 had a major influence on the number of patients receiving cancer screening, diagnosis, and treatment. Oncology clinics were re-profiled to treat COVID-19 patients due to increased demand caused by the rising number of COVID-19 patients being hospitalized. However, as governments gradually reduce travel restrictions, testing numbers are projected to rise once more. Since the COVID-19 pandemic, responding to increased cancer incidence has become a critical medical challenge on a worldwide scale. Because numerous COVID-19 patients had cancer, cancer has been recognized as a risk factor for COVID-19. More study in this area is expected to benefit cancer research by assisting in better understanding the dynamics of infection. This is also expected to raise demand for liquid biopsy products., Market Dynamics:, Drivers: Rise in the prevalence of cancer, On a worldwide basis, the number of cancer patients has grown dramatically. For instance, according to World Health Organization, the leading cause of death is cancer, accounting for nearly 10 million deaths in 2020. Some of the causes of the increased incidence of cancer include environmental factors, cigarette smoking, viral disorders such as Hepatitis B and C, and lifestyle changes. Liquid biopsy provides several advantages over traditional cancer diagnostic procedures, including reduced cost, earlier prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). The liquid biopsy is expected to become the first choice for diagnosis of a wide variety of cancers, such as Central Nervous System (CNS) and pancreatic cancer., Restraints: Certain liquid biopsies have reduced sensitivity, Detecting ctDNA in liquid biopsies is technically difficult since the quantities of DNA of any particular cancer mutation in a cancer patient's plasma might be very low, especially after therapy or surgery. According to the sampling statistics, there may be less than one detectable copy of the ctDNA with the cancer mutation in each sample of plasma from a patient. As a result, even if ctDNA is present in the plasma at a low level, it may not be found in the patient sample. This results in false-negative results in which ctDNA is not discovered despite its presence, decreasing the predictive value of liquid biopsy testing for cancer., Opportunities: The increasing influence of companion diagnostics, Companion diagnostics are tests or assays that assist healthcare practitioners to make treatment decisions for patients based on the optimal response to therapy. Co-development of companion diagnostics with therapeutic goods has the potential to significantly transform the drug development process and accelerate the commercialization of drug candidates. This is done by producing safer medications with improved therapeutic efficacy rapidly and cost-effectively. The market for companion diagnostics has considerable growth potential due to the rising need for high-priced specialized therapies and safer medications. The increasing relevance of companion diagnostics is also propelling the liquid biopsy market growth., Segments Insight, Biomarker Type Insights, Based on the biomarker type, the U.S. Liquid Biopsy Market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), extracellular vesicles (EVs), and other biomarkers. Due to the increased global cancer prevalence, the Circulating Tumor Cells(CTC) category is anticipated to dominate the liquid biopsy market over the forecast period. The cells that break out from primary or secondary cancers and enter the bloodstream are known as Circulating Tumor Cells. The predictive and prognostic biomarkers in various cancers, including lungs, breast, and prostate, are CTC. Additionally, the circulating tumor DNA segment is expected to grow significantly during the forecast period., Sample Insights, Based on the sample, the U.S. Liquid Biopsy Market is segmented into blood samples, urine samples, and others. The Blood sample category is expected to expand at the fastest rate over the review period. A blood test is painless and has no risks, along with this, it cuts down cost and time to diagnose a problem. Blood-based liquid biopsy is popular as it can detect CTCs, cfDNAs, exosomes, and microvesicles. Additionally, the urine sample segment is expected to grow significantly over the forecast period. The urine-based sample collection has various advantages over blood sample collection including increased patient compliance for cancer screening and the ability to monitor patients more frequently. , Application Insights, Based on the application, the U.S. Liquid Biopsy Market is segmented into cancer therapeutic applications, reproductive health, and other therapeutic application. The cancer application category had the most market share in 2020. The growing prevalence of cancer and the increase in research studies on liquid biopsy for cancer applications are driving the growth of this market. A type of test that can be used for cancer screening at an early stage is a liquid biopsy. It can be used to determine how well the treatment is working and whether the cancer has returned. The ctDNA tests may be able to detect more cancers at an early stage, which reduces the risk of death from that cancer., End-User Insights, Based on the end-user, the U.S. Liquid Biopsy Market is segmented into hospitals and laboratories, academic and research centers, and other end users. The laboratories market category had the most market share in 2021. The increased outsourcing of liquid biopsy testing to reference labs is driving the growth of this industry. The revenue growth of hospitals is mainly driven by the emergence of cancer specialty hospitals in developing countries with the availability of advanced procedures, such as liquid biopsy., Recent Developments, In July 2021, Biocept, Inc. has received a South Korean Patent for the Primer-Switch technology, which uses real-time PCR and related analytical methods to discover rare mutations in circulating tumor DNA (ctDNA). In February 2021, Guardant Reveal, the first blood-only liquid biopsy test for detecting residual and recurring illness from a single blood draw, has been made available by Guardant Health, Inc., KEY MARKET SEGMENTS, By Biomarker Types , Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular vesicles (EVS), Other Biomarkers, By Application , Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application, By Sample , Blood Sample, Urine Sample , Other, By End User , Hospitals and Laboratories, Academic and Research Centers, Other End Users, KEY MARKET PLAYERS, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc. , Illumina Inc., MDxHealth SA , Menarini Silicon Biosystems, QIAGEN N.V. , Thermo Fisher Scientific Inc..

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

US Liquid Biopsy Market

Product ID: UCMIR35J2123

$5,300
BUY NOW GET SAMPLE